Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.630.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- MET Receptor Tyrosine Kinase
- c-Met Receptor Tyrosine Kinase
- c Met Receptor Tyrosine Kinase
- Receptor, Hepatocyte Growth Factor
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
- Scatter Factor Receptor
- Receptor, HGF
- HGF Receptor
- Hepatocyte Growth Factor Receptor
- c-met Proteins
- c met Proteins
- MET Proto-Oncogene, Receptor Tyrosine Kinase
- MET Proto Oncogene, Receptor Tyrosine Kinase
- Receptor, Scatter Factor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
-
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018 09; 123:76-82.
-
Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET. Bioorg Chem. 2018 09; 79:163-170.
-
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11).
-
Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer. Future Med Chem. 2017 04; 9(5):469-483.
-
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440.
-
The MET Receptor Tyrosine Kinase Confers Repair of Murine Pancreatic Acinar Cells following Acute and Chronic Injury. PLoS One. 2016; 11(10):e0165485.
-
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
-
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res. 2015 Dec 15; 21(24):5588-600.
-
Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology. 2015 Jan; 148(1):181-191.e17.